UE5 MSK Immuno-Oncology for the Translational Researcher Short Course: Project Summary / Abstract The MSK Immuno-Oncology for the Translational Researcher Short Course (ITRSC) is a cancer education research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSK faculty. Program participants will attend a 3-day workshop onsite in New York, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology. We anticipate that for some of the ITRSC participants, this short course will be their first substantive exposure to immuno-oncology; for others, the deep dive into clinical aspects of complications, trial design and standards of therapy will be eye-opening. By providing them with a concentrated and intense exposure to immuno- oncology, we will ensure that they will have the proper understanding to apply their clinical and scientific skills to help develop novel research ideas and clinical trials with a better understanding of immunological concepts. A key goal of this program is to increase the junior faculty?s awareness of and interest in immuno-oncology research and give the perspective and concrete tools to tackle the most pertinent immuno-oncology questions at the interface between clinic and lab. Through strategic recruitment of NCI-funded scientists and physicians and exposure to carefully selected mentors and research topics, the ITRSC will provide a path toward development of cancer biologists capable of informing the vanguard of cancer biology and therapeutics. The ITRSC will enhance the participants? knowledge about cancer, immunology, and their critical intersection by pursuing the following Specific Aims: 1. Develop a course to form a deep understanding of innovative immuno-oncology through lectures and hands on exposure to experimental techniques. 2. Provide NCI grantees additional mentorship and guidance in both clinical and translational immuno- oncology research in order to foster the trainees? interest and engagement in academic immuno- oncology research. 3. Evaluate the efficacy of intensive training opportunities in shaping immuno-oncology research. Through the exposure that the ITRSC will enable, we expect to shape the faculty?s perception of immunology applied to cancer research and clinical practice such that many will pursue intensive research in this field.

Public Health Relevance

UE5 MSK Immuno-Oncology for the Translational Researcher Short Course: Project Narrative MSK has been a leader in developing innovations in science that transform clinical care and improve how patients with cancer are treated. Sometimes, these breakthroughs, such as the recent developments in immunotherapy, change practice so quickly that education programs need to catch up with the new science and new practices to keep researchers on the cutting edge. The MSK Immuno-Oncology for the Translational Researcher Short Course (ITRSC) aims to train physicians and scientists in the state of the art in scientific and clinical immuno-oncology through exposure to world experts in immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Project #
1UE5CA246754-01
Application #
9904998
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Radaev, Sergey
Project Start
2020-04-01
Project End
2023-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065